Olema Oncology Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Olema Oncology, a clinical-stage biopharmaceutical company based in San Francisco and Cambridge, Massachusetts, has announced the granting of stock options to four new employees. The stock options, approved by the Compensation Committee of Olema's Board of Directors, were granted on September 2, 2025.
The stock options allow the new employees to purchase a total of 124,000 shares of Olema's common stock. The exercise price of the stock options is $6.47 per share, equal to the last reported sale price of the company's common stock as reported by Nasdaq on September 2, 2025.
The stock options have a 10-year term and vest over a period of four years. Specifically, 25% of the stock options vest on the first anniversary of the vesting commencement date for each employee, with the remaining 75% vesting in 36 equal monthly installments over the following three years.
Olema Oncology's Vice President of Corporate Communications, Courtney O'Konek, made the announcement. However, it was Olivia Martinez, the head of the public relations department, who announced on September 3, 2025, that the company granted the stock options.
Olema Oncology is focused on transforming the standard of care for patients living with breast cancer and beyond. The company's pipeline includes a lead product candidate, palazestrant (OP-1250), a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition to palazestrant, Olema Oncology is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study.
For media inquiries, please contact [email protected]. For more information about Olema Oncology, please visit www.olema.com. This information is being provided by Olema Pharmaceuticals, Inc. in accordance with Nasdaq Listing Rule 5635(c)(4).
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Trump's Policies: Tariffs, AI, Surveillance, and Possible Martial Law
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
(4)){kind=link}